Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia.

Copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone), Cu-ATSM, labeled with a positron emitting isotope of copper ((60)Cu, (61)Cu, (62)Cu or (64)Cu) has been shown, in vitro and in vivo, to be selective for hypoxic tissue. In silico studies have explored the mechanism of its hypoxia selectivity, and clinical studies with this agent have shown non-invasive imaging data that is predictive of a cancer patients' response to conventional therapy. This Perspective discusses the evolution of Cu-ATSM, how its selectivity can be improved upon, and where this metal-ligand platform could be taken in the future.

[1]  J. Lewis,et al.  Copper radionuclides and radiopharmaceuticals in nuclear medicine. , 1996, Nuclear medicine and biology.

[2]  Morand Piert,et al.  Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  J. Dilworth,et al.  Probing the mechanism of hypoxia selectivity of copper bis(thiosemicarbazonato) complexes: DFT calculation of redox potentials and absolute acidities in solution. , 2006, Dalton transactions.

[4]  X. Hou,et al.  Separation of no-carrier-added 64Cu from a proton irradiated 64Ni enriched nickel target. , 2002, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[5]  J. White,et al.  Copper complexes of thiosemicarbazone-pyridylhydrazine (THYNIC) hybrid ligands: a new versatile potential bifunctional chelator for copper radiopharmaceuticals. , 2006, Inorganic chemistry.

[6]  M J Welch,et al.  Efficient production of high specific activity 64Cu using a biomedical cyclotron. , 1997, Nuclear medicine and biology.

[7]  Jason S. Lewis,et al.  Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents. , 2005, Nuclear medicine and biology.

[8]  Y Yonekura,et al.  Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Janice M. Y. Brown,et al.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.

[10]  Y. Fujibayashi,et al.  Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  F. O’Sullivan,et al.  Hypoxia and Glucose Metabolism in Malignant Tumors , 2004, Clinical Cancer Research.

[12]  R. P. Maickel,et al.  Subcellular distribution of tissue radiocopper following intravenous administration of 67Cu-labeled Cu-PTSM. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[13]  C. Reynolds,et al.  Hypoxia-targeting copper bis(selenosemicarbazone) complexes: comparison with their sulfur analogues. , 2003, Journal of the American Chemical Society.

[14]  Y. Yonekura,et al.  62Cu-labeling of human serum albumin-dithiosemicarbazone (HSA-DTS) conjugate for regional plasma volume measurement: application of new 62Zn/62Cu generator system. , 1990, Chemical & pharmaceutical bulletin.

[15]  J. Bowsher,et al.  Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  Nobuyuki Oyama,et al.  Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells , 2001, Annals of nuclear medicine.

[17]  Jason S. Lewis,et al.  Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro , 1998, European Journal of Nuclear Medicine.

[18]  P Vaupel,et al.  Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. , 2001, Seminars in oncology.

[19]  C Clifton Ling,et al.  Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor mo , 2005, International journal of radiation oncology, biology, physics.

[20]  J. Lacy,et al.  Performance of a 62Zn/62Cu generator in clinical trials of PET perfusion agent 62Cu-PTSM. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  C. Ling,et al.  Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. , 2005, Nuclear medicine and biology.

[22]  A. Scott,et al.  Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  M. Raichle,et al.  Copper-62-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  J. Dilworth,et al.  Bifunctional chelators for copper radiopharmaceuticals: the synthesis of [Cu(ATSM)-amino acid] and [Cu(ATSM)-octreotide] conjugates. , 2007, Dalton transactions.

[25]  Rebecca L Aft,et al.  Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose. , 2003, Cancer research.

[26]  Jason J. Davis,et al.  Fluorescence studies of the intra-cellular distribution of zinc bis(thiosemicarbazone) complexes in human cancer cells. , 2005, Chemical communications.

[27]  Y. Fujibayashi,et al.  Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone). , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  James L Tatum,et al.  Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy , 2006, International journal of radiation biology.

[29]  R. Langlois,et al.  Production of 64Cu on the Sherbrooke TR-PET cyclotron , 2003 .

[30]  T. Buettner,et al.  Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  W. Eckelman,et al.  Semi-remote production of [64Cu]CuCl2 and preparation of high specific activity [64Cu]Cu-ATSM for PET studies , 2005 .

[32]  M. Welch,et al.  Evaluation of copper-labeled bifunctional chelate-albumin conjugates for blood pool imaging. , 1993, Nuclear medicine and biology.

[33]  D J Terris,et al.  Head and Neck Cancer: The Importance of Oxygen , 2000, The Laryngoscope.

[34]  Michael J Welch,et al.  Positron-emitting isotopes produced on biomedical cyclotrons. , 2005, Current medicinal chemistry.

[35]  C. Reynolds,et al.  Towards new transition metal-based hypoxic selective agents for therapy and imaging. , 2001, Journal of inorganic biochemistry.

[36]  P. Cutler,et al.  High purity production and potential applications of copper-60 and copper-61. , 1999, Nuclear medicine and biology.

[37]  Michael J. Welch,et al.  In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  Mark A Mintun,et al.  Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. , 2003, International journal of radiation oncology, biology, physics.

[39]  D. Petering.  Physico-chemical properties of the antitumor agent, 3-ethoxy-2-oxobutyraldehyde bis (thiosemicarbazonato) copper(II) , 1972 .

[40]  Y. Yonekura,et al.  Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. , 1999, Nuclear medicine and biology.

[41]  Kenneth A Krohn,et al.  Imaging hypoxia and angiogenesis in tumors. , 2005, Radiologic clinics of North America.

[42]  A. Nunn,et al.  Nitroimidazoles and imaging hypoxia , 1995, European Journal of Nuclear Medicine.

[43]  J. Ballinger,et al.  Imaging hypoxia in tumors. , 2001, Seminars in nuclear medicine.

[44]  F. Szélecsényi,et al.  Excitation functions of proton induced nuclear reactions on enriched 61Ni and 64Ni: Possibility of production of no-carrier-added 61Cu and 64Cu at a small cyclotron , 1993 .

[45]  John Humm,et al.  Tumor Hypoxia Imaging , 2006, Clinical Cancer Research.

[46]  J. Dilworth,et al.  An unusual dimeric structure of a Cu(I) bis(thiosemicarbazone) complex: implications for the mechanism of hypoxic selectivity of the Cu(II) derivatives. , 2002, Journal of the American Chemical Society.

[47]  James W Fleshman,et al.  Copper-64-pyruvaldehyde-bis(N(4)-methylthiosemicarbazone) for the prevention of tumor growth at wound sites following laparoscopic surgery: monitoring therapy response with microPET and magnetic resonance imaging. , 2002, Cancer research.

[48]  G. Umbricht,et al.  Radiolabeling of proteins with radioisotopes of copper using p‐carboxyalkylphenylglyoxal bis‐(4N‐methylthiosemicarbazone) (TSC) bifunctional chelates , 1990 .

[49]  D J Kadrmas,et al.  Rapid dual-tracer PTSM+ATSM PET imaging of tumour blood flow and hypoxia: a simulation study , 2006, Physics in medicine and biology.

[50]  P. W. Hochachka,et al.  Going malignant: the hypoxia-cancer connection in the prostate. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[51]  Y. Yonekura,et al.  Mitochondria-selective reduction of 62Cu-pyruvaldehyde bis(N4-methylthiosemicarbazone) (62Cu-PTSM) in the murine brain; a novel radiopharmaceutical for brain positron emission tomography (PET) imaging. , 1993, Biological & pharmaceutical bulletin.

[52]  E. Moros,et al.  Monitoring the effect of mild hyperthermia on tumour hypoxia by Cu-ATSM PET scanning , 2006, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[53]  H. Petering,et al.  THE ANTI-TUMOR ACTIVITY OF 2-KETO-3-ETHOXYBUTYRALDEHYDE BIS(THIOSEMICARBAZONE) AND RELATED COMPOUNDS. , 1964, Cancer research.

[54]  S. Teat,et al.  Structural trends in copper(II) bis(thiosemicarbazone) radiopharmaceuticals , 2003 .

[55]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[56]  D. Hedley,et al.  Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Jason S. Lewis,et al.  Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships , 2002, JBIC Journal of Biological Inorganic Chemistry.

[58]  S. Cherry,et al.  Evaluation of copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) for tissue blood flow measurement usina a trapped tracer model , 1994, European Journal of Nuclear Medicine.

[59]  A. Padhani.  Where are we with imaging oxygenation in human tumours? , 2005, Cancer imaging : the official publication of the International Cancer Imaging Society.

[60]  Y. Yonekura,et al.  Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG. , 2003, Nuclear medicine and biology.

[61]  M. Alber,et al.  Imaging oxygenation of human tumours , 2006, European Radiology.

[62]  Jason S. Lewis,et al.  Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[63]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[64]  T. Roskams,et al.  Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer , 2002, International journal of cancer.

[65]  N. Sadato,et al.  Evaluation of62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer , 2000 .

[66]  M J Welch,et al.  Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[67]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[68]  Jason S. Lewis,et al.  Redox-active metal complexes for imaging hypoxic tissues: structure–activity relationships in copper(II) bis(thiosemicarbazone) complexes , 1998 .

[69]  Y. Yonekura,et al.  Hyperfixation of copper-62-PTSM in rat brain after transient global ischemia. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[70]  J. Rasey,et al.  Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. , 1990, Radiation research.

[71]  Y. Yonekura,et al.  Basic characterization of 64Cu-ATSM as a radiotherapy agent. , 2005, Nuclear medicine and biology.

[72]  Kazutoshi Suzuki,et al.  An improved 62Zn/62Cu generator based on a cation exchanger and its fully remote-controlled preparation for clinical use. , 2006, Nuclear medicine and biology.

[73]  J. Eary,et al.  [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[74]  G. Hortobagyi.  Can we cure limited metastatic breast cancer? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Y. Yonekura,et al.  Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. , 2006, Nuclear medicine and biology.

[76]  C. Reynolds,et al.  Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. , 2002, Journal of medicinal chemistry.

[77]  S Mutic,et al.  A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. , 2001, International journal of radiation oncology, biology, physics.